Welcome to our dedicated page for Soligenix news (Ticker: SNGX), a resource for investors and traders seeking the latest updates and insights on Soligenix stock.
Soligenix, Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company headquartered in Princeton, New Jersey. The company is dedicated to developing and commercializing products that address unmet medical needs, particularly in the areas of inflammation, oncology, and biodefense. Soligenix operates through two business segments: Specialized BioTherapeutics and Public Health Solutions.
Under the Specialized BioTherapeutics segment, Soligenix focuses on rare disease treatments. Key projects include HyBryte™ (SGX301), a novel photodynamic therapy using synthetic hypericin for cutaneous T-cell lymphoma (CTCL). HyBryte™ has shown promising results in Phase 3 clinical trials and is on track for regulatory approvals in the United States and Europe. Other development programs include SGX302 for psoriasis, SGX942 for oral mucositis in head and neck cancer, and SGX945 for Behçet's disease.
The Public Health Solutions segment emphasizes vaccine development and biodefense. Notable projects include RiVax®, a ricin toxin vaccine candidate, and thermostable vaccine candidates for filoviruses such as Marburg and Ebola. These vaccines are developed using the company's proprietary heat stabilization platform technology, ThermoVax®. Soligenix has also been active in developing CiVax™, a vaccine candidate for COVID-19.
Recent achievements include additional patents for their trivalent filovirus vaccine platform and positive clinical trial results for HyBryte™. Financially, the company reported a net loss for the quarter ended March 31, 2024, but successfully raised $4.75 million through a public offering. Soligenix has also secured significant non-dilutive government funding to support its various development programs.
Partnerships with esteemed institutions like the University of Hawaiʽi at Mānoa and funding from organizations such as the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA) further bolster Soligenix's research and development efforts. With a robust pipeline and strategic collaborations, Soligenix aims to deliver significant long-term value to its shareholders and address critical healthcare needs globally.
Soligenix, Inc. (Nasdaq: SNGX) reported its Q3 2020 financial results, highlighting recent achievements in clinical trials for SGX301 and SGX942. SGX301 demonstrated a statistically significant response for early-stage cutaneous T-cell lymphoma in a pivotal Phase 3 trial, with plans for FDA submission. Revenue for the quarter was $0.6 million, a decline from $1.3 million in Q3 2019. The net loss narrowed to $1.8 million, down from $2.7 million last year. The company holds approximately $11.3 million in cash, positioning it for future developments within its rare disease pipeline.
Soligenix, a late-stage biopharmaceutical company focused on rare diseases, will present at upcoming virtual investor conferences. CEO Christopher J. Schaber will speak at the Virtual Fall Investor Summit on November 17, 2020, at 9:30 AM ET. Another presentation is scheduled for the A.G.P. Virtual Healthcare Symposium on November 19, 2020. Soligenix develops innovative therapies, including SGX301 for cutaneous T-cell lymphoma and SGX942 for oral mucositis. The company is also advancing a ricin toxin vaccine and therapies for antibiotic-resistant infections.
Soligenix announced significant progress in its Phase 3 FLASH study of SGX301 for treating cutaneous T-cell lymphoma (CTCL). Continued treatment for 6 months showed a 49% response rate, increasing from 40% in the previous cycle. Key findings include effective treatment of both patch and plaque lesions, with 66% of patients opting for extended therapy. The drug's safety profile remains robust, with no systemic hypericin detected. Soligenix is preparing for FDA application while targeting commercialization or partnerships for SGX301, emphasizing its potential as a transformative therapy.
Soligenix, a late-stage biopharmaceutical company, announced that Christopher J. Schaber, Ph.D., its CEO, will present at the BIO Investor Forum from October 13-15, 2020. The presentation will be available on-demand for attendees. Soligenix focuses on developing products for rare diseases, including SGX301 for cutaneous T-cell lymphoma and dusquetide for oral mucositis in head and neck cancer. Their Public Health Solutions segment includes a ricin toxin vaccine and other vaccine candidates for emerging infectious diseases. For more details, visit www.soligenix.com.
Soligenix, Inc. (Nasdaq: SNGX) announced the publication of nonclinical results on filovirus protein antigens, including for Ebola and Marburg viruses, revealing successful thermostabilization. Collaborative research with the University of Colorado and University of Hawaiʻi at Mānoa indicates that heat-stable vaccine formulations can be developed, maintaining stability for 12 weeks at 40°C. The company aims to expedite its Marburg virus vaccine evaluations. This advancement aligns with their joint COVID-19 vaccine effort, CiVax™, to enhance vaccine distribution reliability in regions with unstable power supplies.
Soligenix, Inc. (Nasdaq: SNGX) hosted an investor webcast on September 10, 2020, showcasing its COVID-19 vaccine candidate, CiVax™, developed from its thermostabilized glycoprotein vaccine platform. Collaborating with the University of Hawaiʻi, the platform focuses on multivalent vaccines, showing potential for broad applicability, particularly for vulnerable populations. Preclinical results indicate strong immune responses following vaccination. The company aims to address urgent needs for effective COVID-19 prevention amidst the pandemic.
Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company, announces that its CEO, Christopher J. Schaber, PhD, will present at two upcoming virtual investor conferences. The first is the Cantor Virtual Global Healthcare Conference on September 15, 2020, at 1:20 PM ET, with a live presentation available online. The second is the Lake Street Capital Markets' 4th Annual Best Ideas Growth Conference on September 17, 2020, which includes one-on-one and group meetings. Soligenix focuses on developing treatments for rare diseases and has multiple ongoing programs.
Soligenix, Inc. (SNGX) announced an Investor Webcast Event on September 10, 2020, to discuss its CiVax™ COVID-19 vaccine development using a thermostabilized glycoprotein platform. The prototype vaccine demonstrates strong immunity induction in preclinical studies, with notable safety in high-risk populations. Combined with its ability to remain stable at high temperatures, CiVax™ aims to meet urgent vaccination needs. Experts will present, followed by a Q&A session. The event invites questions beforehand and will provide a recording post-webcast.
Soligenix, Inc. (Nasdaq: SNGX), a biopharmaceutical company focused on rare diseases, announced that its CFO, Jonathan Guarino, will present at the LD Micro Conference from September 1-4, 2020. Guarino's presentation is scheduled for September 4 at 9:40 AM ET. The conference will be held virtually. The company specializes in developing treatments like SGX301 for cutaneous T-cell lymphoma and vaccine candidates for various diseases. For more details on the conference, visit LD Micro Conference.
Soligenix, Inc. (SNGX) announced its Q2 2020 financial results and recent accomplishments. Revenue was $0.5 million, down from $1.4 million in Q2 2019. Net loss increased to $2.8 million, or ($0.10) per share, primarily due to higher R&D costs ($2.2 million). Positive developments include significant results from the Phase 3 FLASH trial for SGX301, with a statistically significant treatment response (p=0.04). Enrollment was completed for the SGX942 trial, with top-line results expected in Q4 2020. The company maintains a cash position of approximately $11.2 million, bolstered by government funding.
FAQ
What is the current stock price of Soligenix (SNGX)?
What is the market cap of Soligenix (SNGX)?
What does Soligenix, Inc. specialize in?
What are the key projects under Soligenix's Specialized BioTherapeutics segment?
What is ThermoVax®?
What achievements has Soligenix recently made?
Who are some of Soligenix's key partners?
What financial milestones has Soligenix achieved?
What is HyBryte™?
What is CiVax™?
What is RiVax®?
What are Soligenix's key areas of focus in vaccine development?
